论文部分内容阅读
目的 观察法国A +C群脑膜炎球菌多糖疫苗对 7～ 14岁儿童接种后的安全性、免疫原性和免疫持久性。方法 观察组 6 0人 ,接种剂量为 10 0 μg/ 0 .5ml/人 ,对照组 30人接种维生素B1;免疫前、免疫后 1月、1年、2年和 3年分别收集血液标本 ,用ELISA方法进行抗体水平检测。结果 疫苗接种后人体反应轻微 ,6 0人中仅 2人(3.3% )出现中度发烧 ,有 3人 (5 % )出现局部红晕 ,48h后反应全部消失。免疫后 1个月 ,A群和C群抗体 4倍增长率分别为 94.4%和 96 .3% ;免疫后 1年、2年和 3年 ,A群和C群抗体 4倍增长率均为 10 0 %。结论 该疫苗较安全 ,免疫原性较强 ,且更具免疫持久性。
Objective To observe the safety, immunogenicity and immune persistence of French A + C meningococcal polysaccharide vaccine in children aged 7-14 years. Methods 60 patients in the observation group were inoculated with a dose of 100 μg / 0.5ml per human, and 30 in the control group were inoculated with vitamin B1. Blood samples were collected before immunization, 1 month, 1 year, 2 years and 3 years after immunization with ELISA method for antibody level detection. Results The body reaction was mild after vaccination. Only 2 out of 60 people (3.3%) experienced moderate fever, and 3 (5%) developed partial flush, and the reaction disappeared after 48h. At 1 month after immunization, the 4-fold growth rates of group A and group C antibodies were 94.4% and 96.3% respectively. At 1 year, 2 years and 3 years after immunization, the 4-fold growth rates of group A and group C antibodies were all 10 0%. Conclusion The vaccine is safer, more immunogenic and more immune durable.